Cokejoy Pharmaceuticals-B (02171.HK) plans to repurchase up to 5% of the company's shares.

Zhixun finance APP news, Keji Pharmaceutical -B (02171.HK) announced that, approved by the company's shareholders at the annual general meeting held on May 22, 2026, the company has been granted a share repurchase authorization. According to this, the company can repurchase up to 10% of the total number of issued shares (excluding any treasury shares) as of the date of the relevant resolution being passed, up to a maximum of 57.096 million shares of the company.